Please select the option that best describes you:
Topics:
Radiation Oncology • ASTRO 2025
Would patients receiving targeted therapies be eligible for TTFields for brain metastases?
This question is part of our collaboration with ASTRO 2025 to highlight impactful trial data from this year's meeting. This question is inspired by the Plenary Session Presentation "Tumor Treating Fields (TTFields) After Stereotactic Radiosurgery (SRS) for Brain Metastases from Non-Small Cell Lung Cancer (NSCLC BM): Final Results of The Phase 3 METIS Trial" by Dr. Vinai Gondi.
Answer from: Radiation Oncologist at Academic Institution
It is unknown whether NSCLC brain patients receiving targeted therapies should also receive TTFields. The most common patients would be those harboring EGFR mutations or ALK rearrangement. This would need to be studied and should not be presumed to be safe, as other unforeseen toxicities have occurr...
Sign in or Register to read more
Answer from: Radiation Oncologist at Academic Institution
Conceptually, I can certainly hypothesize and conjecture the value of combining TTFields for brain metastases with targeted therapies. However, this specific population was excluded from the current trial, and therefore, we have no direct data to report or answer this question with greater speci...